BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Wednesday reported a loss of $52.6 million in its second quarter.

On a per-share basis, the Brisbane, California-based company said it had a loss of 91 cents.

The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 79 cents per share.

Aimmune Therapeutics shares have fallen 22 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $29.63, an increase of 44 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AIMT at https://www.zacks.com/ap/AIMT